The story has been updated to include comments from Danaher's conference call this morning.

NEW YORK (GenomeWeb News) – Danaher's sales for the third quarter rose 6 percent year over year as its Life Sciences and Diagnostics segment grew almost 11 percent, the company reported today.

For the three months ended Sept. 27, the Washington-based conglomerate saw sales improve to $4.67 billion from $4.42 billion a year ago, edging out the consensus Wall Street estimate of $4.62 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.